Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LumibirdLTS:0FRI -0.57%80 EV-to-EBIT is 27.05 as of Aug. 03, 2026, which is 18% above its 10-year median of 22.99. GuruFocus rates LTS:0FRI with a GF Score™ of 80/100 and a GF Value™ of €16.64 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Lumibird ranks worse than 60% on this metric.
The historical rank and industry rank for Lumibird's EV-to-EBIT or its related term are showing as below:
LTS:0FRI'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.38 Med: 22.99 Max: 100.14
Current: 27.05
During the past 13 years, the highest EV-to-EBIT of Lumibird was 100.14. The lowest was 8.38. And the median was 22.99.
LTS:0FRI's EV-to-EBIT is ranked worse than 60% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.07
vs LTS:0FRI: 27.05
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lumibird's Enterprise Value for the quarter that ended in Dec. 2025 was €545.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumibird's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumibird EV-to-EBIT Related Terms
Lumibird EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lumibird's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lumibird's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumibird EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lumibird's EV-to-EBIT falls into.
Lumibird's current Enterprise Value is €667.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumibird's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €24.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumibird (LTS:0FRI) has a EV-to-EBIT of 27.05 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lumibird and its competitors. This is 18% above median its historical median of 22.99. Over the past decade, Lumibird's EV-to-EBIT has ranged from 8.38 to 100.14. According to the industry distribution chart, Lumibird ranks #63 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 60%.
Is Lumibird's EV-to-EBIT too high?
Lumibird's current EV-to-EBIT of 27.05 is 18% above median its 10-year median of 22.99. Over the past 10 years, this metric has ranged from a low of 8.38 to a high of 100.14. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.07. Lumibird's value of 27.05 is 17.3% above this industry median. Based on the distribution chart, Lumibird ranks #63 out of 105 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lumibird has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #63 out of 105 companies for EV-to-EBIT. This places Lumibird in the lower half of its industry. The industry median EV-to-EBIT is 23.07. Lumibird's value of 27.05 is 17.3% above this benchmark. Historically, Lumibird's own EV-to-EBIT has ranged from 8.38 to 100.14 over the past decade. While the company's 10-year median is 22.99 vs. the industry median of 23.07, Lumibird has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.07, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumibird's current EV-to-EBIT of 27.05 is 17.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lumibird and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumibird's current EV-to-EBIT is 27.05, which is 18% above median its own 10-year median of 22.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (LTS:0FRI) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.64, compared to a current price of €26.30 — trading 58.1% above its estimated fair value. The current EV-to-EBIT is 27.05, which is 18% above median its 10-year median of 22.99 and 17.3% above the Medical Diagnostics & Research industry median of 23.07. Lumibird's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lumibird (LTS:0FRI), the current EV-to-EBIT is 27.05 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumibird (LTS:0FRI) Overvalued in 2026?
Based on GuruFocus' analysis, Lumibird stock appears to be overvalued.
The current stock price of €26.30 is trading 58.1% above its estimated GF Value™ of €16.64.
GuruFocus considers Lumibird to be Significantly Overvalued.
Key valuation signals for LTS:0FRI:
EV-to-EBIT: 27.05 (18% above median its 10-year median of 22.99)
GF Value™: €16.64 vs. price of €26.30 (58.1% above fair value)
Industry Position: 17.3% above the Medical Diagnostics & Research median (#63 of 105)
No single metric tells the full story. See the LTS:0FRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
80GF Score
Get the complete analysis for LTS:0FRI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0FRI has been successfully added to your 
